JP2022547537A5 - - Google Patents
Info
- Publication number
- JP2022547537A5 JP2022547537A5 JP2022515650A JP2022515650A JP2022547537A5 JP 2022547537 A5 JP2022547537 A5 JP 2022547537A5 JP 2022515650 A JP2022515650 A JP 2022515650A JP 2022515650 A JP2022515650 A JP 2022515650A JP 2022547537 A5 JP2022547537 A5 JP 2022547537A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- vegf antagonist
- dose
- composition according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025260627A JP2026072102A (ja) | 2019-09-13 | 2025-12-17 | 眼疾患を治療するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899892P | 2019-09-13 | 2019-09-13 | |
| US62/899,892 | 2019-09-13 | ||
| US202062971405P | 2020-02-07 | 2020-02-07 | |
| US62/971,405 | 2020-02-07 | ||
| PCT/IB2020/058459 WO2021048806A1 (en) | 2019-09-13 | 2020-09-11 | Methods for treating ocular diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025260627A Division JP2026072102A (ja) | 2019-09-13 | 2025-12-17 | 眼疾患を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547537A JP2022547537A (ja) | 2022-11-14 |
| JP2022547537A5 true JP2022547537A5 (cg-RX-API-DMAC7.html) | 2023-08-23 |
| JP7828274B2 JP7828274B2 (ja) | 2026-03-11 |
Family
ID=72521675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515650A Active JP7828274B2 (ja) | 2019-09-13 | 2020-09-11 | 眼疾患を治療するための方法 |
| JP2025260627A Pending JP2026072102A (ja) | 2019-09-13 | 2025-12-17 | 眼疾患を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025260627A Pending JP2026072102A (ja) | 2019-09-13 | 2025-12-17 | 眼疾患を治療するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12649781B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4028128A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7828274B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220062279A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114375201A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020347575A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3149706A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289436A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022003101A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202116802A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021048806A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| AU2020347575A1 (en) | 2019-09-13 | 2022-03-17 | Novartis Ag | Methods for treating ocular diseases |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| TW202337496A (zh) * | 2022-03-17 | 2023-10-01 | 瑞士商諾華公司 | 治療新生血管性年齡相關性黃斑點退化之方法 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| KR20180005753A (ko) | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Vegf를 억제하는 안정하고 가용성인 항체 |
| PL2307458T3 (pl) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| RU2653753C1 (ru) | 2008-06-25 | 2018-05-14 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα |
| PE20120322A1 (es) | 2009-07-07 | 2012-04-14 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante |
| US20160220675A1 (en) | 2013-09-11 | 2016-08-04 | Glenn Abrahmsohn | Hypertonic antimicrobial therapeutic compositions |
| US11104730B2 (en) | 2013-11-20 | 2021-08-31 | Regeneren Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| ES2642723B1 (es) | 2016-05-12 | 2018-10-22 | Servizo Galego De Saúde (Sergas) | Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias. |
| MX2020009140A (es) | 2018-03-16 | 2020-09-28 | Novartis Ag | Metodos para el tratamiento de enfermedades oculares. |
| CN113194993A (zh) | 2018-12-18 | 2021-07-30 | 诺华股份有限公司 | 含高浓度抗vegf抗体的蛋白质溶液配制品 |
| AU2020347575A1 (en) | 2019-09-13 | 2022-03-17 | Novartis Ag | Methods for treating ocular diseases |
-
2020
- 2020-09-11 AU AU2020347575A patent/AU2020347575A1/en active Pending
- 2020-09-11 CA CA3149706A patent/CA3149706A1/en active Pending
- 2020-09-11 CN CN202080063654.2A patent/CN114375201A/zh active Pending
- 2020-09-11 MX MX2022003101A patent/MX2022003101A/es unknown
- 2020-09-11 JP JP2022515650A patent/JP7828274B2/ja active Active
- 2020-09-11 TW TW109131282A patent/TW202116802A/zh unknown
- 2020-09-11 KR KR1020227007553A patent/KR20220062279A/ko active Pending
- 2020-09-11 WO PCT/IB2020/058459 patent/WO2021048806A1/en not_active Ceased
- 2020-09-11 US US17/641,799 patent/US12649781B2/en active Active
- 2020-09-11 EP EP20772435.2A patent/EP4028128A1/en active Pending
-
2021
- 2021-12-27 IL IL289436A patent/IL289436A/en unknown
-
2025
- 2025-12-17 JP JP2025260627A patent/JP2026072102A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025169389A5 (cg-RX-API-DMAC7.html) | ||
| Campochiaro et al. | Anti–vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside | |
| US10266588B2 (en) | Method of treating osteoarthritis with an antibody to NGF | |
| IL277333B1 (en) | VEGF antagonists for use in the treatment of diabetic macular edema | |
| FI3795181T3 (fi) | Amd:n hoito aav2-variantilla ja afliberseptillä | |
| FI4364724T3 (fi) | Korkean pitoisuuden VEGF-reseptorifuusioproteiinia sisältäviä formulaatioita | |
| US20060293270A1 (en) | Methods and compositions for treating ocular disorders | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| CA3025258C (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| JP2024519629A5 (cg-RX-API-DMAC7.html) | ||
| NZ596663A (en) | Use of vegf antagonists in intraocular neovascular disease treatment | |
| JP2021522180A5 (cg-RX-API-DMAC7.html) | ||
| Fang et al. | Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema | |
| Bertschinger et al. | Yoga can be dangerous—glaucomatous visual field defect worsening due to postural yoga | |
| JP2018529766A5 (cg-RX-API-DMAC7.html) | ||
| US20070027102A1 (en) | Methods and compositions for treating macular degeneration | |
| Hwang et al. | Intravitreous treatment of severe ocular von Hippel–Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial | |
| Mehta et al. | Intravitreal bevacizumab for the treatment of refractory diabetic macular edema | |
| Ober et al. | Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection | |
| RU2010108395A (ru) | Способ лечения центральных субретинальных кровоизлияний | |
| Esteve et al. | Coats’ disease with macular oedema responsive to aflibercept and argon laser | |
| CN102872464A (zh) | 一种新型脉络膜新生血管基因治疗药物及其用途 | |
| Lee et al. | Angiographically documented macular ischemia after single bevacizumab for macular edema secondary to central retinal vein occlusion | |
| Vidyashree et al. | Clinical study: Evaluation of the effect of topical nepafenac on central foveal thickness and visual acuity post panretinal photocoagulation in diabetic retinopathy | |
| Moraes et al. | Epidemiological Analysis of Patients with Vitreoretinal Diseases Undergoing Intravitreal Therapy at a Referral Hospital in the State of Pará |